The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:

Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine
Houston, Texas, USA
The Center for Vaccine Development houses the product development laboratories of the PDP and specifically works on the selection, screening and feasibility of expression platforms for vaccine candidates. In addition it has capabilities for recombinant protein process development to guide technology transfer, training and capacity building for current Good Manufacturing Practice (cGMP) production of vaccine candidates. The portfolio of vaccine programs include hookworm, schistosomiasis, Chagas, leishmaniasis and SARS.

The George Washington University (GW) - Department of Microbiology, Immunology and Tropical Medicine
Washington, DC, USA
For the hookworm and schistosomiasis vaccine programs, GW leads the clinical testing in collaboration with the Brazilian partners. Laboratory and field work includes preclinical immunological assessment, potency testing and assessment of human immune response to vaccines with and without antigenic challenge.

University of Kansas
Lawrence, Kansas, USA
The University of Kansas collaborates with the product development laboratories in Houston to assess the vaccine candidates’ preformulation studies, biophysical characterization and the high throughput screening of GRAS (Generally Regarded as Safe) reagents to be used as potential vaccine stabilizers.

Fundacao Oswaldo Cruz (FIOCRUZ)
Belo Horizonte, Minas Gerais, Brazil
FIOCRUZ, the research arm of the Brazilian ministry of health, serves as the center for epidemiological assessments and provides the clinical testing sites in rural Brazil, including a clinic and field laboratories specifically for the hookworm and schistosomiasis programs. In addition, Biomanguinhos, FIOCRUZ is the public sector vaccine manufacturer that will serve as the Brazilian manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the hookworm vaccines.

James Cook University (JCU)
Brisbane, Queensland, Australia
JCU performs research and development activities primarily for target candidate discovery, early evaluation, characterization and ranking for hookworm and schistosomiasis programs.

London School of Hygiene and Tropical Medicine (LSHTM)
London, England
LSHTM designs and conducts statistical analysis for the clinical trials in Brazil. They also conduct mathematical modeling and cost-effectiveness analysis which have informed our global access strategy including vaccine development, introduction, distribution and financing.

Instituto Butantan
Sao Paulo, Brazil
Insituto Butantan is a public sector vaccine manufacturer in Sao Paulo, Braziland that serves as the Brazilian manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the schistosomiasis vaccines.

The Institute of Parasite Diseases, Chinese Centers for Disease Control and Prevention
Beijing, China
IPD carries out research and preclinical testing of the hookworm vaccine candidates by utilizing an adapted hamster model against the human hookworm Necator americanus.

BIRMEX
Mexico City, Mexico
Birmex is Mexico’s leading public sector vaccine manufacturer and serves as the Mexican manufacturing partner for technology transfer, scale-up process development and clinical grade manufacture of the Chagas and Lesihmaniasis vaccines.

National Institutes of Health (NIH), Laboratory of Malaria and Vector Research, Vector Molecular Biology Section
Bethesda, Maryland, USA
These laboratories handle preclinical work for the leishmaniasis vaccine program. This work includes assessment of immunogenicity and efficacy of these vaccines candidates.

New York Blood Center
New York, New York, USA
The New York Blood Center handles preclinical work for the Sabin PDP SARS vaccine program.  This work includes assessment of immunogenicity of the vaccine candidates.

University of Texas Medical Branch (UTMB)
Galveston, Texas, USA
UTMB handles preclinical work for the Sabin PDP SARS vaccine program.  This work includes assessment of immunogenicity efficacy of the vaccine candidates.